A South Korean research group has reported in a new paper that artificial intelligence and light-based genetic tools can work ...

Imdelltra combined with chemotherapy and PD-L1 therapy showed a 71% objective response rate and 82% disease control rate in ...

On one side, there is the need to accelerate the electoral campaign by advancing proposals. On the other, there's the issue ...

Builders have expressed concern over a slew of labor, environmental, and safety mandates they argue have suppressed competitiveness.

Explore the challenges of CNS drug development for neurodegenerative diseases and the complexity of measuring disease ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced ...

In 2020, Oregon became the first state in America to decriminalize all drugs. Was it a catastrophic mistake? Has this famously progressive city been mugged by reality? Reason visited Portland and ...

While discussing his plans for a physical, President Trump once again bragged about the score he achieved on his last ...

BlueRock Therapeutics reports positive 36-month results from phase I trial of bemdaneprocel for treating Parkinson’s disease: Berlin, Germany Wednesday, October 8, 2025, 18:00 H ...

Introduction Only symptomatic treatments are available for patients with Parkinson’s disease (PD), the second most common chronic neurodegenerative disease worldwide, and it is therefore imperative to ...